SHARESIFT
Healthcare · data ~15-min delayed
136.9 EUR +1.82%
| Price | 136.9 EUR |
| Day change | +1.82% |
| Market cap | 59.52B |
| 52-week range | 100.7 – 148.8 |
| P/E (trailing) | 25.1 |
| Dividend yield | 1.61% |
| Payout ratio | 40.37% |
| Return on equity | 8.13% |
| Debt / equity | 41% |
| Beta | 0.81 |
| Sector | Healthcare |
| Value score | 27 / 100 |
How the value score is calculated: 13 published tests, weighted to 100.
Merck KGaA (MRK.DE) scores 27/100 on this site's value model, in the lower band: most of the valuation measures it checks sit on the richer side. It trades at 25.1 times trailing earnings and is classified in Healthcare. The dividend yield is 1.61%, paid from 40% of earnings. Return on equity is 8%, with debt at 41% of equity. On its filings it passes 5 of the nine Piotroski checks, a mixed picture. Its Altman Z-Score places it in the grey zone. These are automated readings of reported figures, not a recommendation.
Piotroski F-Score 5 / 9 — nine pass/fail checks on profitability, leverage and efficiency, comparing the latest financial year with the one before.
Altman Z-Score 2.96 — Grey zone.
Updated · prices ~15-min delayed, fundamentals as last reported
Open full interactive analysis →See how it ranks: Germany stocks by value score
Value scoring · Piotroski F-Score · Altman Z · technicals · dividends — free, no sign-up.